228246-71-7

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 62-53-3 aniline 
• 252285-02-2 (R)-1-(1,2,3,4-tetrahydro-naphthalen-1-yl)-piperidin-4-one 
• 49800-23-9 (R)-(+)-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride 
• 77542-18-8 1-methyl-1-ethyl-4-oxopiperidinium iodide 

Downstream Products

• 228246-70-6 (R)-4-phenylamino-1-(1,2,3,4-tetrahydro-naphthalen-1-yl)-piperidine-4-carboxylic acid amide 

Relevant academic research and scientific papers

High-affinity, non-peptide agonists for the ORL1 (Orphanin FQ/nociceptin) receptor

The discovery of 8-(5,8-dichloro-1,2,3,4-tetrahydro-napthalene-2-yl)-1- phenyl-1,3,8-triazaspiro[4.5]decan-4-one, 1a, as a high-affinity ligand for the human ORL1 (orphanin FQ/nociceptin) receptor led to the synthesis of a series of optimized ligands. The

1,3,8-triazaspiro[4,5]decan-4-one derivatives

The present invention relates to compounds of the formula wherein R1 and R2 are each independently hydrogen, lower alkyl, lower alkoxy or halogen; R3 is phenyl, which is unsubstituted or substituted by lower alkyl, CF3, lower alkoxy or halogen; R4 is hydrogen, lower alkyl, lower alkenyl, -C(O)-lower alkyl, -C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylene-C(O)O-lower alkyl, lower alkantriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH(OH)CF3, phenyl or benzyl, R5 and R6 are each independently hydrogen, phenyl, lower alkyl or di-lower alkyl or R5 and R6 together with the carbon atoms to which they are bound form a phenyl ring, or R5 and one of R1 or R2 together with the carbon atoms to which they are bound form a saturated or unsaturated 6 membered ring, A is a 4-7 membered saturated ring, their racemates and the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof which are agonists and/or antagonists of the OFQ receptor.